m+Medelevator.RU
← Поиск публикаций
Science translational medicine · 2012

Exome sequencing can improve diagnosis and alter patient management.

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПоддержка правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Dixon-Salazar Tracy J, Silhavy Jennifer L, Udpa Nitin, Schroth Jana, Bielas Stephanie, Schaffer Ashleigh E, Olvera Jesus, Bafna Vineet, Zaki Maha S, Abdel-Salam Ghada H, Mansour Lobna A, Selim Laila, Abdel-Hadi Sawsan, Marzouki Naima, Ben-Omran Tawfeg, Al-Saana Nouriya A, Sonmez F Müjgan, Celep Figen, Azam Matloob, Hill Kiley J, Collazo Adrienne, Fenstermaker Ali G, Novarino Gaia, Akizu Naiara, Garimella Kiran V, Sougnez Carrie, Russ Carsten, Gabriel Stacey B, Gleeson Joseph G

Аннотация

The translation of "next-generation" sequencing directly to the clinic is still being assessed but has the potential for genetic diseases to reduce costs, advance accuracy, and point to unsuspected yet treatable conditions. To study its capability in the clinic, we performed whole-exome sequencing in 118 probands with a diagnosis of a pediatric-onset neurodevelopmental disease in which most known causes had been excluded. Twenty-two genes not previously identified as disease-causing were identified in this study (19% of cohort), further establishing exome sequencing as a useful tool for gene discovery. New genes identified included EXOC8 in Joubert syndrome and GFM2 in a patient with microcephaly, simplified gyral pattern, and insulin-dependent diabetes. Exome sequencing uncovered 10 probands (8% of cohort) with mutations in genes known to cause a disease different from the initial diagnosis. Upon further medical evaluation, these mutations were found to account for each proband's disease, leading to a change in diagnosis, some of which led to changes in patient management. Our data provide proof of principle that genomic strategies are useful in clarifying diagnosis in a proportion of patients with neurodevelopmental disorders.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты